Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naxitamab plus GM-CSF for refractory high-risk neuroblastoma with bone and/or bone marrow disease
2023-508587-29-00Phase 2Authorised
- Sponsor
- Y-mAbs Therapeutics, Inc.
- Start
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of naxitamab and sargramostim in neuroblastoma, sponsored by Y-mAbs Therapeutics, Inc. Primary endpoint: Objective response rate. Planned start Apr 2018; status: authorised.
02
Drugs
naxitamabsargramostim
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2023-508587-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508587-29-00.